480 related articles for article (PubMed ID: 28494176)
1. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
2. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Noack J; Choi J; Richter K; Kopp-Schneider A; Régnier-Vigouroux A
Cell Death Dis; 2014 Sep; 5(9):e1425. PubMed ID: 25255218
[TBL] [Abstract][Full Text] [Related]
3. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Bektas M; Johnson SP; Poe WE; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1053-8. PubMed ID: 19597728
[TBL] [Abstract][Full Text] [Related]
4. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
[TBL] [Abstract][Full Text] [Related]
6. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
7. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
[TBL] [Abstract][Full Text] [Related]
8. Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Sun S; Lee D; Lee NP; Pu JK; Wong ST; Lui WM; Fung CF; Leung GK
J Neurooncol; 2012 Sep; 109(3):467-75. PubMed ID: 22763762
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
10. Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Zhang Z; Wang Y; Chen J; Tan Q; Xie C; Li C; Zhan W; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1289-1296. PubMed ID: 27832326
[TBL] [Abstract][Full Text] [Related]
11. β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
Liu S; Zhou L; Zhao Y; Yuan Y
Oncol Rep; 2015 Aug; 34(2):943-51. PubMed ID: 26062577
[TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
13. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
[TBL] [Abstract][Full Text] [Related]
14. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Riccitelli E; Giussani P; Di Vito C; Condomitti G; Tringali C; Caroli M; Galli R; Viani P; Riboni L
PLoS One; 2013; 8(6):e68229. PubMed ID: 23826381
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Borges KS; Castro-Gamero AM; Moreno DA; da Silva Silveira V; Brassesco MS; de Paula Queiroz RG; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
J Cancer Res Clin Oncol; 2012 Mar; 138(3):405-14. PubMed ID: 22160182
[TBL] [Abstract][Full Text] [Related]
16. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Gupta SK; Mladek AC; Carlson BL; Boakye-Agyeman F; Bakken KK; Kizilbash SH; Schroeder MA; Reid J; Sarkaria JN
Clin Cancer Res; 2014 Jul; 20(14):3730-41. PubMed ID: 24838527
[TBL] [Abstract][Full Text] [Related]
17. Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
Combs SE; Bohl J; Elsasser T; Weber KJ; Schulz-Ertner D; Debus J; Weyrather WK
Int J Radiat Biol; 2009 Feb; 85(2):126-37. PubMed ID: 19280465
[TBL] [Abstract][Full Text] [Related]
18. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
19. Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Hanif F; Perveen K; Malhi SM; Jawed H; Simjee SU
Toxicol In Vitro; 2018 Oct; 52():306-313. PubMed ID: 30003979
[TBL] [Abstract][Full Text] [Related]
20. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
